Cytokines

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at BTIG's Virtual Biotechnology Conference 2021

Retrieved on: 
Tuesday, August 3, 2021

To learn more about ZyVersa and its inflammasome ASC inhibitor, IC 100, or its phase 2a-ready cholesterol efflux mediator for renal disease (VAR 200), please request a one-on-one meeting.

Key Points: 
  • To learn more about ZyVersa and its inflammasome ASC inhibitor, IC 100, or its phase 2a-ready cholesterol efflux mediator for renal disease (VAR 200), please request a one-on-one meeting.
  • ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs.
  • Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/zyversa-therapeutics-ceo-stephe...

Chairman of the 180 Life Sciences Clinical Advisory Board, Professor Jagdeep Nanchahal, has Been Invited To Present a Keynote Talk at the British Society for Surgery of the Hand (BSSH) at the Autumn Scientific Meeting in Oxford UK on September 9, 2021

Retrieved on: 
Monday, August 2, 2021

Dr. James Woody, 180 Life Sciences Chief Executive Officer, stated We are especially pleased Professor Nanchahal can present his scientific work to clinical colleagues who have extensive experience of treating patients with late-stage disease.

Key Points: 
  • Dr. James Woody, 180 Life Sciences Chief Executive Officer, stated We are especially pleased Professor Nanchahal can present his scientific work to clinical colleagues who have extensive experience of treating patients with late-stage disease.
  • Professor Jagdeep Nanchahal commented, By systematically analyzing tissues normally discarded at the time of surgery, we were able to identify a potential therapeutic target and progress through to testing in patients with early stage Dupuytrens disease.
  • 180 Life Sciences is leading the research into solving one of the worlds biggest drivers of disease inflammation.
  • The Companys primary, most advanced platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor) which is in the clinic.

Global Interleukin Inhibitors Market (2020 to 2026) - Featuring AbbVie, AstraZeneca and Sanofi Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, July 23, 2021

The global Interleukin Inhibitors market is segmented on the basis of product type and applications.

Key Points: 
  • The global Interleukin Inhibitors market is segmented on the basis of product type and applications.
  • Based on the product type, the market is segmented as IL-1 inhibitors, IL-5 inhibitors, IL-6 inhibitors, IL-17 inhibitors, and IL-23 inhibitors.
  • Further, based on the geography, the global Interleukin Inhibitors market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
  • Insights about market determinants which are stimulating the global Interleukin Inhibitors market.

InveniAI Announces Successful Completion of Milestone in its Collaboration with PRISM BioLab Focused on Designing Novel Inflammasome-Targeted Therapeutic Candidates

Retrieved on: 
Tuesday, July 20, 2021

The first program to be prioritized for progressing into IND enabling studies is INVA8003, a first-in-class pan-inflammasome inhibitor.

Key Points: 
  • The first program to be prioritized for progressing into IND enabling studies is INVA8003, a first-in-class pan-inflammasome inhibitor.
  • A key event in the innate immune response is formation of the inflammasome, a multi-protein complex where PYCARD is a pivotal component.
  • Under the terms of the collaboration, PRISM will receive an undisclosed milestone payment from InveniAI.
  • PRISM BioLab Co., Ltd., based in Japan, is a biotechnology company with proprietary small molecule drug discovery platform PepMetics Technology.

INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer’s Association International Conference 2021

Retrieved on: 
Monday, July 19, 2021

In that study, we were able to demonstrate that XPro1595 neutralizes soluble TNF and decreases biomarkers of neuroinflammation across multiple measures and assays in Alzheimers patients.

Key Points: 
  • In that study, we were able to demonstrate that XPro1595 neutralizes soluble TNF and decreases biomarkers of neuroinflammation across multiple measures and assays in Alzheimers patients.
  • The data suggest that decreasing neuroinflammation results in significant improvements in biomarkers of neurodegeneration and synaptic function.
  • XPro1595 could have substantial beneficial effects in patients with Alzheimers and other neurodegenerative diseases by decreasing neuroinflammation.
  • DN-TNF is currently being developed for COVID-19 complications (Quellor), cancer (INB03), Alzheimers and Treatment Resistant Depression(XPro1595), and NASH (LIVNate).

BioCure Technology Inc. Announces Closing of Financing

Retrieved on: 
Thursday, July 15, 2021

The net proceeds from the non-brokered private placement are intended to be used for general working capital, research and development.

Key Points: 
  • The net proceeds from the non-brokered private placement are intended to be used for general working capital, research and development.
  • Biocure is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer.
  • Biocure, headquartered in Korea, has joint venture partners in Asia and Europe with planned clinical trials commencing in 2021.
  • Biocure is in the process of pre-clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG- Filgrastim as well as Ranibizumab.

Sigyn Therapeutics Announces Rapid Elimination of Hepatic Toxins from Human Blood Plasma

Retrieved on: 
Thursday, July 15, 2021

Sigyn Therapy is a proprietary blood purification technology designed to deplete pathogens, toxins and inflammatory targets from the bloodstream of treated patients.

Key Points: 
  • Sigyn Therapy is a proprietary blood purification technology designed to deplete pathogens, toxins and inflammatory targets from the bloodstream of treated patients.
  • 32% of ammonia was eliminated from human blood plasma in one hour and an average elimination of 37% was reported at four hours.
  • We created Sigyn Therapy to overcome the limitations of previous blood purification technologies, stated Jim Joyce, Chairman and CEO of Sigyn Therapeutics.
  • In previous studies, Sigyn Therapy demonstrated the simultaneous depletion of endotoxin, TNF-a, IL-6 and IL-1b from human blood plasma.

Early Results of BetterLife Preclinical Study Showing AP-003 (rhIFNa2b) has Similar Potent Efficacy Against Different Variants of COVID-19

Retrieved on: 
Thursday, July 15, 2021

Early data show potent and similar anti-viral activity against the COVID-19 Wuhan reference strain (EC50=0.51), Alpha (B.1.1.7, UK, EC50=1.26) and Beta (B.1.351, South Africa, EC50=0.25) variants.

Key Points: 
  • Early data show potent and similar anti-viral activity against the COVID-19 Wuhan reference strain (EC50=0.51), Alpha (B.1.1.7, UK, EC50=1.26) and Beta (B.1.351, South Africa, EC50=0.25) variants.
  • Further studies are ongoing to validate these early results and to test AP-003 activity against Gamma (Brazil), Delta (India) and Lambda (Peru) variants.
  • The rhIFN2b, a Type I interferon, is a naturally occurring protein integral to the bodys first line of anti-viral defenses.
  • The broad mechanism of action of interferon is such that our scientists hypothesized it could be equally effective against different variants.

AmMax Bio to Present at the 2nd Annual LifeSci Partners Private Company Summer Symposium

Retrieved on: 
Wednesday, July 14, 2021

A potent inhibitory CSF1R monoclonal antibody, AMB-05X represents a therapeutic platform targeting serious macrophage-driven inflammatory, fibrotic and neovascular diseases.

Key Points: 
  • A potent inhibitory CSF1R monoclonal antibody, AMB-05X represents a therapeutic platform targeting serious macrophage-driven inflammatory, fibrotic and neovascular diseases.
  • The CSF1 receptor, via its binding to two regulatory cytokines, CSF1 and IL-34, is critically involved in the regulation of macrophages and related cells in multiple biological processes across many organ systems, making it an attractive target with broad therapeutic applications.
  • Overactivation of the CSF1/IL-34 CSF1R axis substantially contributes to the inflammatory, fibrotic and neovascular characteristics inherent in many diseases.
  • AmMax is enrolling patients in a Phase 2 clinical program for tenosynovial giant cell tumor (TGCT) and has achieved nonclinical proof-of-concept in both neovascular age-related macular degeneration (nAMD) and idiopathic pulmonary fibrosis (IPF).

Global Erythropoietin Drugs Market to 2027 by Drug Class, Product, Application, Regional Outlook - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021

The "Global Erythropoietin Drugs Market By Drug Class, By Product, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Erythropoietin Drugs Market By Drug Class, By Product, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global Erythropoietin Drugs Market size is expected to reach $20.2 billion by 2027, rising at a market growth of 11.8% CAGR.
  • The post-abbreviated new drug application (ANDA) is getting approvals and there is a high success rate of erythropoietin drugs in chemotherapy-induced anaemia.
  • Therefore, the impact of the COVID-19 pandemic is likely to have a positive impact on the erythropoietin drug market.